DKSH has successfully signed a strategic partnership with Glenmark, a research-led, global pharmaceutical company, for a comprehensive portfolio of services to offer a wide range of Glenmark’s products in Vietnam. The products will be distributed by local partners after importation.
Ho Chi Minh City, November 28, 2023 – DKSH’s Business Unit Healthcare, a leading Market Expansion Services in Asia and beyond, has successfully entered a strategic partnership with Glenmark to bring a wide range of their products focusing on dermatology, respiratory, cardiovascular, and women health to Vietnam. Entrusted to be Glenmark’s strategic partner, DKSH leverages its expertise and global experience to enhance accessibility for the Vietnamese market.
Under the strategic partnership with DKSH Vietnam, Glenmark’s key line-up in diverse categories, such as Candid, Klenzit Saferon, Combiwave and many other high-quality products will be supplied to Vietnam.
Tomas Mihal, Vice President and Regional Business Head - Asia Pacific, Glenmark Pharmaceuticals Ltd. stated: “As our commitment to creating ‘A new way for a new world’ with science and innovation, we believe that DKSH is the right partner to support us in increasing market potential for Glenmark’s range of products in Vietnam. This partnership motivates us to keep exploring science to create breakthrough therapies for the healthcare industry.”
Shilpa Jani Sr., General Manager and Country Head of Vietnam, Thailand, Cambodia, and Export Markets at Glenmark, added that the partnership will bring in synergies and increase market access for these high-quality products to Vietnamese patients. The partnership will also aid in addressing unmet medical needs in the near future in Vietnam.
Phillip Wray, General Director, DKSH Pharma Vietnam, shared: “We believe that the new partnership with Glenmark is aligned with our commitment to provide healthcare for all. With our in-depth knowledge and extensive network, we will closely work with Glenmark to realize their business goals in the healthcare industry in Vietnam while enriching people’s lives with high quality and innovative products.”
This partnership with Glenmark is part of the eight key strategic new partnerships that DKSH Business Unit Healthcare has entered this year in Vietnam to strengthen its position as the strategic healthcare solutions partner while providing healthcare for all.
About Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Limited (BSE: 532296 | NSE: GLENMARK) is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. In Vivo/Scrip 100 positions Glenmark amongst the Top 100 Companies Ranked by R&D and Pharmaceutical Sales, 2021; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies Ranked by Sales, 2021. The company has also been Great Place To Work® CertifiedTM in India for FY 2023. Glenmark’s Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 2.9 million lives over the last decade through its CSR interventions. For more information, visit www.glenmarkpharma.com
About DKSH
DKSH’s purpose is to enrich people’s lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution, and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 37 markets with 32,600 specialists, generating net sales of CHF 11.3 billion in 2022. The DKSH Business Unit Healthcare is a trusted healthcare solutions partner across Asia and beyond. With around 7,990 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2022. www.dksh.com/hec